Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POST-BIO: Postbiotics and Pembrolizumab in RM HNSCC
NCT07485296Phase 2Recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Jan 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Gruppo Oncologico Nord Ovest. Primary endpoint: Changes in oral and fecal microbiota composition at 2 years. Started Jan 2026; status: recruiting.
02
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07485296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07485296.